Laboratory and clinical studies in indolent lymphoma. Improvements in outcome in indolent lymphoma will come from study of the molecular determinants of outcome to treatment. Once these determinants are identified and validated, new drug treatments can be tested in subsequent clinical trials. Surrogate markers are useful to identify more rapidly whether the novel agent is targeting the lymphoma cells. Illustration by Paulette Dennis.